Mometasone
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Mometasone: From Unspecified Original Indication to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Mometasone’s original indication is not recorded in this evidence pack, and the drug is currently not marketed in Taiwan. The TxGNN model predicts potential activity against Primary Cutaneous T-Cell Lymphoma, but this is currently supported only by 2 incidental case-report mentions and no registered clinical trials — one of which actually reports mometasone failing to treat a lymphoma-mimicking skin condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no indication data on record in this evidence pack) |
| Predicted New Indication | Primary Cutaneous T-Cell Lymphoma |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for mometasone in this evidence pack, and the drug’s original indication is also not recorded. Based on general pharmacological knowledge, mometasone (furoate) is a synthetic glucocorticoid typically formulated for topical, intranasal, or inhaled use, with anti-inflammatory and immunomodulatory effects mediated through the glucocorticoid receptor.
Corticosteroids are broadly used in dermatology, including for inflammatory and lymphoproliferative skin conditions, which offers a plausible mechanistic rationale for a TxGNN link to a cutaneous T-cell lymphoma. However, the two literature items retrieved for this prediction do not clearly support that rationale: one describes mometasone as an unsuccessful treatment for cutaneous pseudolymphoma (a condition that mimics but is not itself primary cutaneous T-cell lymphoma), and the other is a pediatric case report of mycosis fungoides that does not mention mometasone treatment or outcome at all. Neither reference constitutes positive efficacy evidence, so the mechanistic plausibility should be treated as speculative pending stronger data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40821495 | 2025 | Case report | Proceedings (Baylor University Medical Center) | Cutaneous pseudolymphoma (a lymphoma-mimicking condition) in a 62-year-old woman was treated unsuccessfully with mometasone and tacrolimus before switching to tapinarof |
| 25442255 | 2015 | Case report | Journal of Cutaneous Pathology | Case of an 11-year-old boy with CD8+CD56+ cytotoxic mycosis fungoides (a form of primary cutaneous T-cell lymphoma); abstract does not mention mometasone treatment or outcome |
Taiwan Market Information
Mometasone is not currently marketed in Taiwan; no approved licenses are on record.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA warning/label data is a blocking data gap for this candidate — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: There are no registered clinical trials, no confirmed MOA data, and no original-indication data for context. The only two literature references are incidental case reports rather than targeted efficacy studies, and one explicitly documents mometasone failing to treat a related lymphoproliferative skin condition. Combined with a blocking safety data gap and no current Taiwan market presence, the evidence does not support advancing this candidate at this time.
To proceed, the following is needed:
- TFDA label/warning and contraindication data (currently a blocking gap, DG001)
- Confirmed mechanism of action from DrugBank (DG002)
- Original indication history for mometasone to establish a baseline for repurposing comparison
- Targeted clinical or preclinical evidence specific to primary cutaneous T-cell lymphoma (not incidental mentions in unrelated case reports)
- Reassessment of Taiwan market strategy given current non-marketed status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.